Abstracts tagged "morbidity and mortality and scleroderma"

Abstract Number: 727 • 2019 ACR/ARP Annual Meeting
Mortality and Morbidity in Scleroderma Renal Crisis: A Systematic Literature Review
Hyein Kim¹, Frédéric Lefebvre ², Sabrina Hoa ³ and Marie Hudson ⁴, ¹The University of British Columbia, Vancouver, Canada, ²University of Montreal, Montreal, Canada, ³University of Montreal, Montreal, QC, Canada, ⁴Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: The introduction of angiotensin converting enzyme (ACE) inhibitors in the early 1970s resulted in marked improvement in clinical outcomes of scleroderma renal crisis (SRC).Despite…
Abstract Number: 855 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Systemic Sclerosis and Breast Cancer and the Effects on Treatment Outcome
Pichaya O-charoen¹, Katherine Glass², William Messner³ and Soumya Chatterjee⁴, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH
Background/Purpose: Breast cancer has been shown to be more prevalent in patients with systemic sclerosis (SSc) compared to that in the general population. A close…
Abstract Number: 706 • 2012 ACR/ARHP Annual Meeting
Excess Mortality From Atherosclerotic Cardiovascular Disease in Systemic Sclerosis Compared to Lupus and Rheumatoid Arthritis
Amish J. Dave¹, Bharathi Lingala², David Fiorentino³, Eswar Krishnan⁴ and Lorinda Chung⁵, ¹Stanford University, Stanford, CA, ²Dermatology, Stanford University, Redwood City, CA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Medicine, Standford University, Palo Alto, CA, ⁵Rheumatology, Stanford Univ Medical Center, Palo Alto, CA
Background/Purpose: Patients with autoimmune connective tissue diseases (CTD), including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), are at increased risk for atherosclerotic cardiovascular disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].